| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 20, 2022
Darlene Noci, A.L.M. promoted to Chief Development Officer
Benjamin Lane, Ph.D. promoted to Senior Vice President, Technical Operations
Darlene Noci, A.L.M. promoted to Chief Development Officer Benjamin Lane, Ph.D. promoted to Senior Vice President, Technical Operations CAMBRIDGE, Mass., July 20, 2022 /PRNewswire/ -- Nuvalent,...
-
Jul 13, 2022Preclinical activity of ALK-selective inhibitor NVL-655 in a lorlatinib-resistant model of NSCLC with a compound resistance mutation continues to support potential for best-in-class profile
Preclinical activity of ALK-selective inhibitor NVL-655 in a lorlatinib-resistant model of NSCLC with a compound resistance mutation continues to support potential for best-in-class profile...
-
Jun 21, 2022
Preliminary dose-escalation data anticipated in second half of 2022 for ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors
First patient dosed in ALKOVE-1 Phase 1/2 clinical trial of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors
Preliminary dose-escalation data anticipated in second half of 2022 for ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors...
-
Jun 2, 2022
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that...
-
May 12, 2022
Two clinical-stage programs ongoing for potential best-in-class ROS1 and ALK-selective inhibitors
On-track for selection of two additional development candidates in 2022
Ended the first quarter of 2022 with $272.7 million in cash, cash equivalents, and marketable securities to support planned operations into 2024
Two clinical-stage programs ongoing for potential best-in-class ROS1 and ALK-selective inhibitors On-track for selection of two additional development candidates in 2022 Ended the first quarter of...
-
Apr 8, 2022NVL-520 showed strong preclinical activity against diverse ROS1 fusion partners and kinase-domain resistance mutations, as well as in a ROS1-driven model of glioblastoma
NVL-520 showed strong preclinical activity against diverse ROS1 fusion partners and kinase-domain resistance mutations, as well as in a ROS1-driven model of glioblastoma NVL-655 demonstrated...
-
Apr 7, 2022
Nuvalent, Inc. (NASDAQ: NUVL), a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that...
-
Mar 31, 2022Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies
Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ --...
-
Mar 29, 2022NVL-655 IND cleared by FDA, supporting planned initiation of ALKOVE-1 Phase 1/2 clinical trial in patients with ALK-positive NSCLC and other solid tumors in second quarter of 2022
NVL-655 IND cleared by FDA, supporting planned initiation of ALKOVE-1 Phase 1/2 clinical trial in patients with ALK-positive NSCLC and other solid tumors in second quarter of 2022 Enrollment...
-
Mar 8, 2022Data supports clinical investigation of NVL-520 and NVL-655 across various ROS1 or ALK fusion partners, resistance mutations, and tumor types
Nuvalent, Inc., (Nasdaq: NUVL) a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced multiple preclinical data presentations...
The information in Nuvalent’s press releases is accurate only as of the date of issuance. Nuvalent assumes no duty to update or revise the information contained in the press releases after their original release date.
